Acquisition of MorphoSys AG by Novartis AG approved

Summary:

The German Federal Cartel Office (Bundeskartellamt) has approved the planned acquisition of MorphoSys AG, a biotechnology company based in Planegg near Munich, by the Swiss pharmaceutical company Novartis AG. MorphoSys develops medicines, particularly for leukemia, while Novartis has a broad presence in various therapeutic areas, including oncology. The acquisition was reviewed to ensure that it would not significantly impede competition in the development of new medicines against a specific type of leukemia. The investigation found that a large number of alternative compounds are being developed, and generics are expected to emerge, thereby maintaining effective competition in the market. The Bundeskartellamt determined that the acquisition does not pose a significant threat to effective competition in the affected markets, and the approval was granted within the monthly review period.